SCHEMBL9965979

SCHEMBL9965979

C[C@@H]1CN(C)C[C@H](C)N1Cc1ccccn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
HRH3 Q9Y5N1 2/20 0.48
KMT2A Q03164 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C19 P33261 1/20 0.45
KCNH2 Q12809 1/20 0.43
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
PKM P14618 1/20 0.41
HRH1 P35367 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
CASP6 P55212 1/20 0.40
SIRT1 Q96EB6 1/20 0.40
IKBKB O14920 2/20 0.40
PRKAG1 P54619 2/20 0.40
PRKAA1 Q13131 2/20 0.40
NEK1 Q96PY6 2/20 0.40
PRKAB1 Q9Y478 2/20 0.40
DDB1 Q16531 1/20 0.39
CRBN Q96SW2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12835921 0.86 LMNA (0.50) LMNAHRH3KMT2ACYP1A2CYP2C19
SCHEMBL9963407 0.83 LMNA (0.45) LMNAHRH3KMT2ACYP1A2CYP2C19
SCHEMBL18390924 0.83 KMT2A (0.44) LMNAHRH3KMT2ACYP1A2CYP2C19
SCHEMBL12835958 0.83 OPRM1 (0.46) LMNAHRH3KMT2ACYP1A2CYP2C19
SCHEMBL1088353 0.81 CASP6 (0.52) LMNAHRH3KMT2ACYP1A2CYP2C19
SCHEMBL9965922 0.80 HRH3 (0.51) LMNAHRH3KMT2ACYP1A2CYP2C19
SCHEMBL12836066 0.77 CYP1A2 (0.53) LMNAKMT2ACYP1A2CYP2C19KCNH2
SCHEMBL1101159 0.75 GPR119 (0.48) LMNAALDH1A1
SCHEMBL27274747 0.75 LMNA (0.58) LMNAKMT2ACYP1A2CYP2C19MEN1
SCHEMBL3165425 0.74 MC4R (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354403-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-01-15 US disclosed
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME, CORP. (US) 2012-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157432-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 LMNA 1824/4885HRH3 250/4885KMT2A 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.